Skip to content
Parakho

Rubicon Research Ltd

NSE RUBICONBSE 544578rubicon.co.inInvestor relations

Q1 FY27, unaudited

Revenue
₹534.34 Cr
Profit after tax
₹84.78 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations534.34—1,753.96
Other income5.68—7.73
Total income540.02—1,761.68
Employee benefit expense85.67—256.29
Finance costs9.29—42.17
Depreciation & amortisation15.14—45.26
Total expenses429.65—1,441.15
Profit before tax110.37—320.53
Tax expense25.59—73.80
Profit after tax84.78—246.74
Total comprehensive income80.05—249.72
Earnings per share
Earnings per share, basic₹5.13₹15.52
Earnings per share, diluted₹5.08₹15.31

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q1 FY27

Rubicon Research reported Q1 FY27 revenue from operations of INR534 crores, EBITDA of INR131 crores, and PAT of around INR85 crores, representing year-on-year growth of 51%, 65%, and over 95% respectively. The quarter included the first consolidation impact of the Arinna Lifesciences acquisition, which contributed roughly INR12 crores to revenue with no material EBITDA impact. Management also announced the acquisition of a manufacturing facility in New Jersey, USA, progress on FDA compliance at the Pithampur site, and a leadership transition in which the CFO will move to a Chief Commercial Officer role.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 55 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.